update desk

Israeli study finds cannabis oil improves autism-related symptoms in teens

A new Israeli study shows that more than 80 percent of children with autism-related symptoms who took cannabis oil enjoyed moderate to significant improvement in their condition.

Pharmicists supply patients with prescribed medical marijuana at the "Tikun Olam" store in Tel Aviv, on April 10, 2016. Tikun Olam Ltd. is the first, largest and foremost supplier of medical cannabis in Israel, and is one of leading medical cannabis companies in the world. April 10, 2016. Photo by Hadas Parush/Flash90.
Pharmicists supply patients with prescribed medical marijuana at the "Tikun Olam" store in Tel Aviv, on April 10, 2016. Tikun Olam Ltd. is the first, largest and foremost supplier of medical cannabis in Israel, and is one of leading medical cannabis companies in the world. April 10, 2016. Photo by Hadas Parush/Flash90.

A new Israeli study shows that more than 80 percent of children with autism-related symptoms who took cannabis oil enjoyed moderate to significant improvement in their condition.

A six-month study at Ben-Gurion University in the Negev and Soroka Medical Center in Beersheva found that 30 percent of patients reported significant improvement and 53.7 percent of patients reported moderate improvement regarding symptoms such as seizures, tics, depression, restlessness and rage attacks after taking the cannabidiol-rich treatment with an addition of 1.5 percent THC on a regular basis.

The study, funded by medical marijuana firm Tikun Olam and titled “Real Life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy,” tested 188 teenagers on the autism spectrum between 2015 and 2017.

After treatment concluded, 66.8 percent of patients said they had a good quality of life, compared to the 31.3% who identified their lives as such prior to the report, and 63.5 percent said they were in positive moods, as compared to 42 percent prior to the beginning of the study.

The authors lauded the success of the study and said they want to move on to double-blind placebo-controlled trials.

You have read 3 articles this month.
Register to receive full access to JNS.

Just before you scroll on...

Israel is at war. JNS is combating the stream of misinformation on Israel with real, honest and factual reporting. In order to deliver this in-depth, unbiased coverage of Israel and the Jewish world, we rely on readers like you. The support you provide allows our journalists to deliver the truth, free from bias and hidden agendas. Can we count on your support? Every contribution, big or small, helps JNS.org remain a trusted source of news you can rely on.

Become a part of our mission by donating today
Topics
Comments
Thank you. You are a loyal JNS Reader.
You have read more than 10 articles this month.
Please register for full access to continue reading and post comments.
Never miss a thing
Get the best stories faster with JNS breaking news updates